SYNERGISTIC MODULATION OF GTPASE HYDROLYSIS AND MTORC1 ACTIVITY IN LRRK2-G2019S PARKINSON’S DISEASE

Sep 29, 2026

Upload by Cart

LRRK2-G2019S mutation drives dysregulation of GTPase hydrolysis, altering mechanistic target of rapamycin complex 1 (mTORC1) signaling in Parkinson’s disease. The study investigates how this mutation affects GTPase activity and downstream cellular processes using an in-vitro PD model. Rapamycin combined with methyl 2-hydroxybenzoate (methyl salicylate) is tested to restore hydrolysis, regulate mTORC1 signaling, improve autophagic fluidity, and reduce neurodegenerative features. Outcomes are evaluated through viability, GTPase activity, ROS, caspase, ELISA, and knockdown plus fluorescence microscopy.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

Abstract

Study Rationale

Hypothesis and Treatment Plan

Experimental Methods

Expected Outcomes and Preliminary Implications

FAQs

What role does the LRRK2-G2019S mutation play in Parkinson’s disease within this study?

The study states that LRRK2-G2019S mutation is implicated in dysregulating GTPase hydrolysis, which impacts mTORC1 signaling in Parkinson’s disease.

What treatment combination is hypothesized to correct the pathway, and what effects are expected?

It hypothesizes Rapamycin (an mTORC1 inhibitor) combined with methyl 2-hydroxybenzoate (methyl salicylate), expected to restore GTPase hydrolysis, regulate mTORC1 signaling, mitigate autophagic fluidity issues, and reduce oxidative stress and apoptosis markers.

How does the study plan to measure cellular changes and mechanism-related outcomes?

It plans to use MTS-based viability, fluorescence-based GTPase activity assays, ROS-Glo, Caspase-Glo 9, ELISA for cell health, and knockdown plus fluorescence microscopy to visualize mTORC1 activity responses.

Sep 29, 2026

Upload by Cart